Century Therapeutics, Inc.

NASDAQ:IPSC

Biotechnology

Healthcare
$1.38 +0.48%

+$0.01 today

Market cap
$250.60M
Beta
1.57
P/E (TTM)
-1.8
EPS (TTM)
-$1.25
52W Low $0.44High $3.04

Volume 1.14M

Average 1.12M

IPSC Sales of Investments

Cash received from selling or redeeming investments.

Century Therapeutics, Inc.NASDAQ: IPSC

Sales of Investments · Q1 FY2026 · quarter ended Mar 2026

Sales of investments turns positive

Q1 FY2026 sales of investments was $28.66M, compared with -$14.89M a year earlier. Trailing-twelve-month sales of investments was $143.66M.

Context

  • Sales of investments amounted to 46.9% of revenue in FY2025, down 2636.3 pp from a year earlier.
  • Sales of investments increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly sales of investments holds near $28.66M or moves back toward the trailing-twelve-month quarterly average of $35.92M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$28.66M-21.7% QoQ
Last fiscal yearDec 2025
-$51.17M-128.9% YoY
LTMMar 2026
$143.66M+25.2% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+292.5%——
1 year-128.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
(51.17M) USD
Year-over-year change
-128.9%

Sales of Investments vs competitors

How IPSC compares with its peers on the latest reported figures

  • IPSC's LTM Mar 2026 sales of investments of $143.66M is the largest of the 8 companies compared; the peer median is $0.
  • Its year-over-year change of +25.2% is the highest of 3, against a peer median of -78.1%.
IPSC Competitors Peer median
Sales of Investments for IPSC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IPSCCentury Therapeutics, Inc.LTM Mar 2026$143.66M +25.2%——
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026$31.29M -56.2%-29.1%20.7%
CUECue Biopharma, Inc.LTM Mar 2026$16.5M —+48.9%50.4%
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$506.11K ——35.8%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
EQEquillium, Inc.LTM Mar 2026$0 -100.0%-48.6%—
TELOTelomir Pharmaceuticals, Inc. Common StockLTM Mar 2026$0 ———
OSTXOS Therapies IncorporatedLTM Mar 2026$0 ———
Peer median (excluding IPSC) $0-78.1%-29.1%28.3%

Competitors are the stored peer set for IPSC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(95.82M)(130.93M)(136.67M)(126.57M)(9.58M)
Depreciation & Amortization3.75M8.44M13.04M13.3M13.1M
Deferred Income Tax000870K(73K)
Stock-Based Compensation4.66M10.67M14.62M12.69M6.84M
Change in Working Capital(2.8M)123.95M9.38M(9.28M)(114.55M)
Accounts Receivables00000
Inventory00000
Accounts Payables(1.85M)(4.79M)(2.36M)(1.47M)1.56M
Other Working Capital(949K)128.73M11.74M(7.81M)(116.12M)
Other Non-Cash Items1.21M1.93M11.28M(1.15M)389K
Operating Cash Flow(89M)14.05M(88.35M)(110.14M)(103.88M)
Capital Expenditures(44.97M)(30.6M)(13.74M)(154K)(848K)
Acquisitions (Net)0(238.22M)0(9.61M)0
Purchases of Investments(330.03M)(254M)(209.03M)(119.55M)(51.17M)
Sales of Investments76.67M271.48M283.9M176.79M(51.17M)
Other Investing Activities0238.22M00210.7M
Investing Cash Flow(298.34M)(13.13M)61.13M47.48M107.5M
Debt Repayment00(10.24M)00
Common Stock Issued221.62M27.16M516K74.56M173K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities36.53M0000
Financing Cash Flow417.77M27.16M(9.73M)74.56M173K
Effect of Forex Changes00000
Net Change in Cash30.43M28.08M(36.94M)11.91M3.8M
Free Cash Flow(133.97M)(16.55M)(102.08M)(110.29M)(104.72M)

Century Therapeutics, Inc.

NASDAQ:IPSC

Intrinsic Alpha fair value

Locked

Current Price

$1.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.